Telomir Pharms - TELO STOCK NEWS

Telomir Pharmaceuticals (NASDAQ:TELO) has announced a significant breakthrough in stabilizing both Silver(I) and Silver(II) ions using Telomir-1, making them biologically compatible for medical applications. This achievement addresses a major limitation in silver-based medical treatments.

The breakthrough opens opportunities in the silver wound dressings market, valued at $1.03 billion in 2024 and expected to reach $1.36 billion by 2030. The broader antimicrobial coatings market is projected to grow from $11.65 billion in 2024 to $33.7 billion by 2031, with a 14.2% CAGR.

Silver(II) offers enhanced healing properties compared to Silver(I), including stronger antimicrobial action, accelerated wound healing, and anti-inflammatory properties. The stabilization through Telomir-1 enables applications in burn care, chronic wound management, and medical device coatings.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough results from preclinical studies of Telomir-1 in human retinal cell lines, showing significant reduction of copper and iron-induced Reactive Oxygen Species (ROS). The studies demonstrate potential treatment for Age-Related Macular Degeneration (AMD), a leading cause of blindness in adults over 50.

The research revealed that Telomir-1 effectively reduced ROS levels at low concentrations, suggesting regulatory properties rather than chelation effects. This indicates promising therapeutic potential for AMD treatment. The compound targets oxidative stress and metal-induced toxicity, key factors in AMD progression, offering a novel approach compared to current treatments that mainly manage symptoms.

The company plans to conduct AMD disease models to evaluate Telomir-1's efficacy in vivo, while also expanding research into other conditions including Wilson's disease, progeria, cancer, Alzheimer's, and infectious diseases.

Telomir Pharmaceuticals (NASDAQ:TELO) announced breakthrough results from preclinical studies showing Telomir-1's ability to fully reverse copper-induced elevation of Reactive Oxygen Species (ROS) and protect cells against copper toxicity in human cell lines. The compound demonstrated effectiveness at doses significantly lower than copper levels, indicating a unique regulatory mechanism beyond copper ion chelation.

The company is exploring Telomir-1's potential applications across multiple conditions where oxidative stress plays a important role, including Wilson's Disease, Alzheimer's, Age-related Macular Degeneration (AMD), cancer, and cardiovascular diseases. Additionally, Telomir is investigating the compound's potential as a treatment for viral infections, particularly avian influenza (bird flu), which has infected over 868 people globally with a 50% mortality rate according to WHO.

The research shows Telomir-1's ability to normalize ROS levels and provide cellular protection, positioning it as a promising therapeutic candidate for addressing oxidative stress-related pathologies and viral infections.

Telomir Pharmaceuticals (NASDAQ:TELO) announced breakthrough findings from a preclinical progeria lifespan study conducted with Nagi Bioscience SA. The study, using C. elegans models with wrn-1 gene mutation, demonstrated that Telomir-1 effectively restored lifespan and normalized accelerated aging effects to levels comparable with normal specimens.

The research focused on treating Progeria, a rare genetic condition affecting fewer than 400 children worldwide, causing rapid aging and premature death. Telomir-1, a novel small molecule, works by controlling excess metal activity, reducing oxidative stress, preventing ferroptosis, lowering inflammation, and regulating telomere shortening processes.

The company has demonstrated Telomir-1's therapeutic potential across multiple areas, including type 2 diabetes reversal and Wilson's disease treatment. Following these positive results, Telomir plans to initiate in vitro studies using human progeria cell lines to further validate the treatment's effectiveness.

Telomir Pharmaceuticals (NASDAQ:TELO) announced significant findings from copper binding studies with Telomir-1, expanding its potential application to Wilson's disease treatment. Preclinical studies showed Telomir-1's ability to bind copper, iron, and zinc ions. The company discontinued its planned osteoarthritis study in dogs due to ethical concerns and is pursuing a new study design with naturally affected elderly dogs.

The company is advancing multiple research initiatives, including studies in Wilson's disease, Type 2 diabetes, Progeria, cancer, and Alzheimer's. Telomir plans IND-enabling safety studies in Q2 2025, targeting IND submission by Q4 2025, with first-in-human trials expected in H1 2026. The company secured additional financing at a 20% premium with no warrants.

Telomir Pharmaceuticals (NASDAQ:TELO) has secured $1 million in equity funding through The Starwood Trust at $7 per share, representing a 20% premium to the closing price. The deal involves restricted common stock with no warrants and follows a previously secured $5 million non-dilutive credit line.

The company recently reported breakthrough preclinical results for Telomir-1, demonstrating age-reversal benefits and potential Type 2 diabetes treatment capabilities. The compound showed significant reductions in fasting plasma glucose levels and improved glucose homeostasis. Telomir-1 targets root causes of aging and disease, including oxidative stress, chronic inflammation, and telomere shortening.

The company is expanding research across multiple conditions, including Progeria, Alzheimer's Disease, Cancer, Wilson Disease, and Osteoarthritis.

Telomir Pharmaceuticals (NASDAQ:TELO) announced groundbreaking preclinical results showing its molecule Telomir-1 effectively reversed key Type 2 diabetes parameters in zebrafish models. The study demonstrated significant reductions in fasting plasma glucose levels, improved glucose homeostasis, and reversed insulin resistance to near pre-diabetic levels, supported by improved HOMA-IR values. The research, conducted with Pentagrit, tested two forms of Telomir-1 at three doses, showing dose-dependent efficacy in normalizing blood glucose and reducing insulin levels. The molecule's mechanism focuses on normalizing iron metabolism to reduce oxidative stress and improve insulin sensitivity. The company is expanding research into progeria, Alzheimer's, osteoarthritis, and cancer models.

Telomir Pharmaceuticals (NASDAQ:TELO) announced groundbreaking preclinical results for Telomir-1, demonstrating significant age-reversal effects in aging model organisms. The study, conducted with Nagi Biosciences SA using advanced microfluidic technology, showed enhanced mobility in older organisms, reduced biological aging, and increased lifespan in treated populations.

The research utilized Caenorhabditis elegans as a model organism, testing two forms of Telomir-1 at different concentrations. The company is expanding research to investigate Telomir-1's potential in treating progeria, collaborating with the Progeria Foundation to study effects on human progeria cell lines.

Telomir Pharmaceuticals (NASDAQ:TELO) announces that its Special Advisor, Dr. Michael F. Roizen, will be featured on Health Uncensored with Dr. Drew on Fox Business Network on Sunday, September 29, 2024, at 5:30 PM EST. Dr. Roizen will discuss the science of longevity and the importance of telomeres in the aging process, focusing on Telomir-1, the company's novel small molecule designed to elongate telomere caps.

The segment will explore how Telomir-1 could potentially transform the treatment of age-related conditions and extend healthy human and canine lifespans. Dr. Roizen, a leading wellness and longevity specialist, will explain the critical role of telomeres in aging and how Telomir-1 offers an opportunity to support stem cell health and target aging mechanisms.

Erez Aminov, Chairman and CEO of Telomir, highlighted the company's ongoing research projects aimed at expediting regulatory applications for Telomir-1 in both veterinary and human applications.